MET and lung carcinoma: Using the EGFR lung cancer model as an example, hyperactivation of the MET pathway either by amplification [49] or by increased receptor protein expression and phosphorylation [50] accounts for 5–10% of all patients resistant to EGFR-TKIs (Fig. 2) [29, 36].